NSE · Healthcare · Drug Manufacturers - General
EPS came in at 1.68 against a street estimate of 1.69 — a miss of 0.6%.
| Document | Date |
|---|---|
| Annual report FY2026 SMS PHARMACEUTICALS LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from Operations: ₹887 Crore (FY2 | 2026-09-04 |
| Investor presentation SMS PHARMACEUTICALS LIMITED – Q1FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹207 crore in Q1FY27, up 6% YoY (₹196 crore in Q1F | 2026-08-01 |
| Q4 FY26 earnings call SMS PHARMACEUTICALS LIMITED – FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue FY26: INR 887 crores, up 13% year-on-year • Q4 FY26 Reven | 2026-05-30 |
| Quarterly results · Q4 FY26 SMS PHARMACEUTICALS LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Full Year FY2025-26 Revenue from Operations: ₹88,687.10 lakhs (up from ₹78,274.81 | 2026-05-22 |
| Quarterly results · Q3 FY26 SMS PHARMACEUTICALS LIMITED – FINANCIAL RESULTS SUMMARY Q3 & 9M FY26 (Quarter/Nine Months Ended 31 December 2025) --- HEADLINE NUMBERS • Q3FY26 Rev | 2026-02-09 |
| Investor presentation SMS PHARMACEUTICALS LIMITED – Q3FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Q3FY26 Revenue: ₹210 crore – grew 21% YoY (Q3FY25: ₹173 crore); down 13% Qo | 2026-02-09 |
| Q2 FY26 earnings call SMS PHARMACEUTICALS LIMITED – Q2 & H1 FY26 SUMMARY HEADLINE NUMBERS • Q2 FY26 Revenue: INR 242.4 crores, up 23% year-on-year • H1 FY26 Revenue: INR | 2025-11-13 |
| Investor presentation · Q2 FY26 SMS PHARMACEUTICALS LIMITED – INVESTOR SUMMARY Q2 & H1 FY26 (NOVEMBER 2025) --- HEADLINE NUMBERS • Q2FY26 Revenue: ₹242.43 crore, up 23% YoY (Q2FY2 | 2025-11-10 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.40 / share ex-date Sep 22, 2025 | 2025-09-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SMS Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.